Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well imetelstat sodium works in treating
younger patients with relapsed or refractory solid tumors. Imetelstat sodium may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.